This is a prospective, randomized, two-armed study to assess the efficacy and safety of isocaloric dietary restriction in the treatment of obese without diabetic for a period of 4 weeks.
This is a randomized, open-label, two arms trial. Based on inclusion and exclusion criteria, 72 eligible patients, who are 18-45 years old, with BMI between 35 to 45kg/m2 are assigned to one of two intervention groups: isocaloric dietary restriction; bariatric surgery. Both groups were given a dietary intervention for a period of 4 weeks (in rigorous supervision confined in inpatient department). The main purpose of this study is to clarify the efficacy of isocaloric dietary restriction, compared to bariatric surgery, in losing weight and improving metabolic factors. This is an investigator-initiated study performed by department of endocrinology and metabolic disease, Ruijin hospital affiliated with Shanghai Jiaotong University School of Medicine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
72
Very low caloric diet
Laparoscopic vertical sleeve gastrectomy
Ruijin hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Body weight
Change of body weight (kg) from baseline measured by study personnel.
Time frame: 4 weeks
Body mass index
Change of BMI \[BMI = weight (kg)/height2(m2)\] from baseline measured by study personnel.
Time frame: 4 weeks
Waist, hip and neck circumference
Waist, hip and neck circumference (cm) measured by study personnel.
Time frame: 4 weeks
Body composition
Body fat mass, fat free mass (kg) and body fat rate measured by DEXA.
Time frame: 4 weeks
Liver fat content
Liver fat content measured by MRI.
Time frame: 4 weeks
Energy expenditure
Energy expenditure measured by metabolic chamber.
Time frame: 4 weeks
Glucose metabolism
including glycated haemoglobin, HOMA-IR, fasting plasma glucose levels and serum insulin levels, post-prandial plasma glucose levels and serum insulin levels (using mixed-meal test).
Time frame: 4 weeks
Lipid profiles
including serum triglycerides, total cholesterol, low-density lipoproteins cholesterol and high-density lipoproteins cholesterol.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Gut hormones
including Glucagon-like peptide 1, gastric inhibitory polypeptide, ghrelin, peptide YY and etc.
Time frame: 4 weeks
Hepatic function
including alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, and alkaline phosphatase.
Time frame: 4 weeks
Renal function
including serum urea nitrogen, serum creatinine, and serum urinary acid.
Time frame: 4 weeks
Endocrine hormones
including thyroid function, sex hormone, insulin-like growth factor and etc.
Time frame: 4 weeks
Appetite (the subjective desire to eat)
assessed according to TFEQ-R21
Time frame: 4 weeks
Adverse events
Safety outcomes
Time frame: 4 weeks
Systolic and diastolic blood pressure
Safety outcomes
Time frame: 4 weeks
Body temperature
Safety outcomes
Time frame: 4 weeks
Pulse rate
Safety outcomes
Time frame: 4 weeks